Sign In
Buy FBIOP
$18.88
+0.0800 (+0.426%)
At Close: Jul 31, 2026
Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference
08:30am, Tuesday, 02'nd Sep 2025
MIAMI, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term
Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
04:05pm, Thursday, 14'th Aug 2025
Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics
10:47am, Friday, 30'th May 2025
Fortress will receive ~$28 million shortly after closing and is eligible for an additional contingent value right (CVR) of up to $4.8 million, plus a 2.5% royalty on future net sales of UNLOXCYT™ (c
Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
04:05pm, Thursday, 15'th May 2025
Emrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkp
Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference
08:00am, Wednesday, 07'th May 2025
MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term v
Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript
07:39pm, Wednesday, 26'th Mar 2025
Fortress Biotech, Inc. (NASDAQ:FBIO ) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder,
FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced a strate
Study is the first randomized, controlled trial examining a vaccine's effectiveness in controlling CMV in recipients of HSCT from vaccinated donors
Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025 Cyprium is eligible to receive royalties and up to $129 million in aggregate development and sales milestones C
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
04:10pm, Thursday, 14'th Nov 2024
Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally adv
Fortress Biotech to Participate in October 2024 Investor Conferences
08:30am, Thursday, 26'th Sep 2024
MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term
Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements
08:30am, Friday, 20'th Sep 2024
MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on acquiring and advancing assets to
Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08:30am, Wednesday, 04'th Sep 2024
MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
04:05pm, Tuesday, 13'th Aug 2024
PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults
Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027
08:30am, Thursday, 25'th Jul 2024
Extends maturity of long-term debt as Fortress‘ late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a fo
